Treatment of end-of-dose wearing-off in Parkinson's disease: Stalevo (R) (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess (R)/Comtan (R) (Entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment
(2005) In European Neurology 53(4). p.197-202- Abstract
- The aim of this study was to evaluate the efficacy of the new optimised levoclopa, Stalevo(R) (levoclopa, carbidopa and entacapone) in patients with Parkinson's disease experiencing end-of-close wearing-off. Treatment with Stalevo was compared to treatment with traditional immediate-release levodopa and dopa-decarboxylase inhibitor (DDCl) formulations along with adjunct entacapone (Comtess(R)/Comtan(R)). A European, open, parallel-group, active treatment-controlled phase IIIb study evaluating 176 patients randomised to switch from their current regimen of levodopa/DDCl to either an equivalent dose of Stalevo or levodopa/DDCl plus entacapone. After 6 weeks, treatments were assessed using the Clinical Global Impression of Change, the Unified... (More)
- The aim of this study was to evaluate the efficacy of the new optimised levoclopa, Stalevo(R) (levoclopa, carbidopa and entacapone) in patients with Parkinson's disease experiencing end-of-close wearing-off. Treatment with Stalevo was compared to treatment with traditional immediate-release levodopa and dopa-decarboxylase inhibitor (DDCl) formulations along with adjunct entacapone (Comtess(R)/Comtan(R)). A European, open, parallel-group, active treatment-controlled phase IIIb study evaluating 176 patients randomised to switch from their current regimen of levodopa/DDCl to either an equivalent dose of Stalevo or levodopa/DDCl plus entacapone. After 6 weeks, treatments were assessed using the Clinical Global Impression of Change, the Unified Parkinson's Disease Rating Scale and a Motor Fluctuations Questionnaire. Over 70% of patients in both the Stalevo, and adjunct entacapone arms felt that they were clinically improved and over 80% experienced a reduction in fluctuations. Although there was no significant difference between Stalevo and levodopa/DDCl plus entacapone with regard to motor improvement and side effects, 81% of patients stated that they preferred treatment with Stalevo compared with taking two separate tablets (i.e. levodopa/DDCl and entacapone). Stalevo was well tolerated and safe when substituted for levodopa DDCl preparations. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/229717
- author
- Brooks, D J ; Agid, Y ; Eggert, K ; Widner, Håkan LU ; Ostergaard, K and Holopainen, A
- organization
- publishing date
- 2005
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- wearing-off, catechol-O-methyltransferase inhibition, inhibitor, dopa-decarboxylase, levodopa, Parkinson's disease, Stalevo (R)
- in
- European Neurology
- volume
- 53
- issue
- 4
- pages
- 197 - 202
- publisher
- Karger
- external identifiers
-
- pmid:15970632
- wos:000231064500006
- scopus:22744453722
- ISSN
- 1421-9913
- DOI
- 10.1159/000086479
- language
- English
- LU publication?
- yes
- id
- 77fbd65f-c0bc-4dff-b5f7-a6dde98d93eb (old id 229717)
- date added to LUP
- 2016-04-01 12:18:23
- date last changed
- 2022-02-11 05:15:10
@article{77fbd65f-c0bc-4dff-b5f7-a6dde98d93eb, abstract = {{The aim of this study was to evaluate the efficacy of the new optimised levoclopa, Stalevo(R) (levoclopa, carbidopa and entacapone) in patients with Parkinson's disease experiencing end-of-close wearing-off. Treatment with Stalevo was compared to treatment with traditional immediate-release levodopa and dopa-decarboxylase inhibitor (DDCl) formulations along with adjunct entacapone (Comtess(R)/Comtan(R)). A European, open, parallel-group, active treatment-controlled phase IIIb study evaluating 176 patients randomised to switch from their current regimen of levodopa/DDCl to either an equivalent dose of Stalevo or levodopa/DDCl plus entacapone. After 6 weeks, treatments were assessed using the Clinical Global Impression of Change, the Unified Parkinson's Disease Rating Scale and a Motor Fluctuations Questionnaire. Over 70% of patients in both the Stalevo, and adjunct entacapone arms felt that they were clinically improved and over 80% experienced a reduction in fluctuations. Although there was no significant difference between Stalevo and levodopa/DDCl plus entacapone with regard to motor improvement and side effects, 81% of patients stated that they preferred treatment with Stalevo compared with taking two separate tablets (i.e. levodopa/DDCl and entacapone). Stalevo was well tolerated and safe when substituted for levodopa DDCl preparations.}}, author = {{Brooks, D J and Agid, Y and Eggert, K and Widner, Håkan and Ostergaard, K and Holopainen, A}}, issn = {{1421-9913}}, keywords = {{wearing-off; catechol-O-methyltransferase inhibition; inhibitor; dopa-decarboxylase; levodopa; Parkinson's disease; Stalevo (R)}}, language = {{eng}}, number = {{4}}, pages = {{197--202}}, publisher = {{Karger}}, series = {{European Neurology}}, title = {{Treatment of end-of-dose wearing-off in Parkinson's disease: Stalevo (R) (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess (R)/Comtan (R) (Entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment}}, url = {{http://dx.doi.org/10.1159/000086479}}, doi = {{10.1159/000086479}}, volume = {{53}}, year = {{2005}}, }